News
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine
![American Express to Hold 2022 Investor Dayhttp://upload.wikimedia.org/wikipedia/commons/3/30/American_Express_logo.svg: By CoolKid1993 at en.wikipedia. Later version(s) were uploaded by Tkgd2007 at en.wikipedia. [Public domain], from Wikimedia Commons](https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBYTQ9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--83cded6416037f9828d8e01e5a5ff220c002a735/300px-American_Express_logo.svg?locale=us){kind=logo}
American Express to Hold 2022 Investor Day
American Express Company (NYSE: AXP) will hold an Investor Day on March 16, 2022, beginning at 1 p.m. Eastern. Chairman and Chief Executive Officer Stephen J. Squeri, Vice Chairman and Chief
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License
![ExxonMobil Announces Ambition for Net Zero Greenhouse Gas Emissions by 2050http://upload.wikimedia.org/wikipedia/commons/1/18/Exxon_Mobil_Logo.svg: By KUsam at en.wikipedia. Later version(s) were uploaded by Cheeselouise at en.wikipedia. [Public domain], from Wikimedia Commons](https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZWc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--c4dbe3169ae447c9c41bd56bfd50efcdfdd87d64/Exxon_Mobil_Logo.svg?locale=us){kind=logo}
ExxonMobil Announces Ambition for Net Zero Greenhouse Gas Emissions by 2050
ExxonMobil today announced its ambition to achieve net zero greenhouse gas emissions for operated assets by 2050, backed by a comprehensive approach to develop detailed emission-reduction roadmaps
U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
Pfizer Inc. (NYSE:PFE) today announced positive top-line results from a Phase 3 study (B74710126) describing the safety and immunogenicity of PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine)
ExxonMobil Expands Interest in Biofuels, Acquires Stake in Biojet AS
ExxonMobil is expanding its interests in biofuels that can help reduce greenhouse gas emissions in the transportation sector, acquiring a 49.9% stake in Biojet AS, a Norwegian biofuels company that
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, today announced they
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
Pfizer Inc. (NYSE: PFE) and Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced an exclusive four-year
ExxonMobil Makes Two Discoveries Offshore Guyana
ExxonMobil today said it made two oil discoveries at Fangtooth-1 and Lau Lau-1 in the Stabroek block offshore Guyana.
The Fangtooth-1 well encountered approximately 164 feet (50 meters) of
Chevron Commits $250,000 to Support Relief Efforts Following Colorado Wildfires
Chevron Corporation (NYSE: CVX) announced today it is making a commitment of $250,000 to support relief efforts underway in the communities affected by the Boulder County wildfires.
“As a leading
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the
Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19
Pfizer Inc. (NYSE: PFE) announced that the U.S. government has committed to purchasing an additional 10 million treatment courses of its COVID-19 oral therapy, PAXLOVID™ (nirmatrelvir [PF-07321332]
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and CEO, at the 40th Annual J.P. Morgan Healthcare Conference on
Advisory: Chevron Corporation’s 4Q 2021 Earnings Conference Call and Webcast
Chevron Corporation (NYSE: CVX), one of the world’s leading energy companies, will hold its quarterly earnings conference call on Friday, January 28, 2022, at 11:00 a.m. ET (8:00 a.m. PT).
Neuer Rekord an der Wall Street: Apple erreicht als erstes Unternehmen einen Börsenwert von drei Billionen Dollar
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and CEO, at the Goldman Sachs 14th Annual Healthcare CEOs
Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 8, 2022. The
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for
Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
Pfizer Inc. (NYSE: PFE) announced an additional agreement with the United Kingdom (UK) government to supply an additional 2.5 million treatment courses of its investigational candidate PAXLOVID™
Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate
Pfizer Inc. (NYSE: PFE) announced today the publication of a post-hoc, interim analysis showing that treatment with VYNDAQEL® (tafamidis meglumine) / VYNDAMAX® (tafamidis) provided a clinically
NIKE, Inc. Reports Fiscal 2022 Second Quarter Results
NIKE, Inc. (NYSE:NKE) today reported fiscal 2022 financial results for its second quarter ended November 30, 2021.
-
Second quarter reported revenues were $11.4 billion, up 1 percent compared to
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement has been reached with the European Commission (EC) and its member states to exercise an option to purchase more
EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate
Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued advice on the use of PAXLOVID™ (nirmatrelvir